For the Inventor, By the Inventor

Enter inventor name

Los Gatos, CA, United States of America

Willem P Stemmer

USPTO Granted Patents = 40 (Patent Applications = 22)

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 2.9

ph-index = 23

Forward Citations = 5,841(Granted Patents)

Location History:

Menlo Park, CA (US) (1994)
Los Gatos, CA (US) (1996 - 2024)

Company Filing History:

Amunix Operating Inc.

Affymax Technologies, N.v.

4. 2 out of 1,168

Glaxo Group Limited

Amunix Pharmaceuticals, Inc

6. 1 out of 560

Affymetrix, Inc.

Bioverativ Therapeutics Inc.

where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Recombinant Polypeptides

Biologically Active Proteins

Growth Hormone Polypeptides

Coagulation Factor IX

Glucose-Regulating Polypeptides

Binding Fusion Proteins

Unstructured Recombinant Polymers

Peptide Library

Polynucleotide Generation

Cellular Engineering

DNA Mutagenesis

Virus Evolution

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071456 - Extended recombinant polypeptides and compositions comprising same (2024-08-27),

2. 10961287 - Extended recombinant polypeptides and compositions comprising same (2021-03-30),

3. 10421798 - Factor VIII compositions and methods of making and using same (2019-09-24),

4. 10000543 - Glucose-regulating polypeptides and methods of making and using same (2018-06-19),

5. 9938331 - Biologically active proteins having increased in vivo and/or in vitro stability (2018-04-10),

6. 9926351 - Extended recombinant polypeptides and compositions comprising same (2018-03-27),

7. 9849188 - Growth hormone polypeptides and methods of making and using same (2017-12-26),

8. 9758776 - Coagulation factor IX compositions and methods of making and using same (2017-09-12),

9. 9540430 - Glucose-regulating polypeptides and methods of making and using same (2017-01-10),

10. 9376672 - Coagulation factor IX compositions and methods of making and using same (2016-06-28),

11. 9371369 - Extended recombinant polypeptides and compositions comprising same (2016-06-21),

12. 9249211 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2016-02-02),

13. 9168312 - Growth hormone polypeptides and methods of making and using same (2015-10-27),

14. 9062299 - Coagulation factor IX compositions and methods of making and using same (2015-06-23),

15. 8957021 - Glucose-regulating polypeptides and methods of making and using same (2015-02-17),

Title: **Willem P. Stemmer: Innovator in Biopharmaceuticals**

Introduction

Willem P. Stemmer, based in Los Gatos, California, is a distinguished inventor with a remarkable portfolio of 40 patents. His work primarily focuses on the field of biopharmaceuticals, particularly in the development of innovative compositions aimed at treating various medical conditions.

Latest Patents

Among his latest contributions to the field are patents related to extended recombinant polypeptides and their compositions. These inventions pertain to biologically active proteins linked to extended recombinant polypeptide (XTEN), alongside isolated nucleic acids that encode these compositions. The implications of his work are vast, targeting the treatment of glucose-related diseases, metabolic disorders, coagulation issues, and growth hormone-related complications. This innovative approach potentially revolutionizes how such conditions are managed in clinical settings.

Career Highlights

Over the years, Stemmer has been associated with notable companies in the biopharmaceutical sector, including Amunix Operating Inc. and Affymax Technologies, N.V. His role in these companies has enabled him to contribute significantly to advancements in therapeutic solutions, leading to a better understanding and treatment of complex diseases.

Collaborations

Collaboration plays a crucial role in Stemmer’s success as an inventor. He has worked alongside esteemed colleagues such as Volker Schellenberger and Chia-wei Wang. These partnerships have fostered a rich environment of shared knowledge and innovation, driving the development of groundbreaking biopharmaceutical applications.

Conclusion

Willem P. Stemmer's contributions to the field of biopharmaceuticals exemplify the impact of innovation in medicine. With 40 patents to his name, his work continues to open new avenues for the treatment of various medical conditions, underscoring the importance of inventors in advancing healthcare technology. His ongoing efforts not only reflect a commitment to innovation but also a dedication to improving patient outcomes through scientific excellence.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…